## VRTX: Vertex Pharmaceuticals Incorpor - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($433.72)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Texas Permanent School Fund Corp Sells 9,892 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251216T123405 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly reduced its stake in Vertex Pharmaceuticals (VRTX) by selling 9,892 shares, representing a 35.4% decrease in its holdings. This divestment comes as company insiders have also been active sellers, with EVP Charles F. Wagner Jr. and Chairman Jeffrey M. Leiden collectively disposing of over 77,000 shares in December. Despite these insider sales and institutional reductions, Vertex Pharmaceuticals recently exceeded Q2 earnings and revenue expectations, maintaining a "Moderate Buy" consensus rating among analysts with an average price target of $498.42.

**2. Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Westwood Holdings Group Inc.**
- Source: MarketBeat | 20251214T140130 | Somewhat-Bullish | Relevance: 100%
- Westwood Holdings Group Inc. significantly increased its stake in Vertex Pharmaceuticals (VRTX) by 108.5% during the second quarter, now holding 154,217 shares worth $68,657,000. Other institutional investors like Vanguard Group Inc. and Jennison Associates LLC also increased their positions. Analyst ratings for VRTX show a "Moderate Buy" consensus with a target price of $498.42, and the company recently surpassed Q2 earnings per share estimates.

**3. Lazard Asset Management LLC Has $213.83 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251214T134930 | Neutral | Relevance: 100%
- Lazard Asset Management LLC has reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 9.8%, now holding 480,310 shares valued at $213.83 million. Insider selling has also occurred, with executives offloading shares worth millions. Despite this, Vertex Pharmaceuticals reported strong Q3 earnings, beating analyst expectations, and carries a "Moderate Buy" consensus rating with a $498.42 price target.

**4. Marex Group plc Invests $2.98 Million in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251214T120314 | Somewhat-Bullish | Relevance: 100%
- Marex Group plc has acquired a new stake in Vertex Pharmaceuticals Incorporated, purchasing 6,703 shares valued at approximately $2.98 million. This investment comes amidst significant insider selling from Vertex executives, with Chairman Jeffrey M. Leiden and EVP Charles F. Wagner, Jr. selling shares worth millions in early December. Institutional investors collectively own a substantial portion of Vertex Pharmaceuticals, while analysts hold a "Moderate Buy" rating with an average target price of $498.42.

**5. Coppell Advisory Solutions LLC Buys 2,846 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251214T100609 | Somewhat-Bullish | Relevance: 100%
- Coppell Advisory Solutions LLC increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 74.1% during the second quarter, acquiring an additional 2,846 shares to hold 6,686 shares valued at approximately $2.95 million. Despite this institutional buying, company insiders have been net sellers, with Chairman Jeffrey M. Leiden and EVP Charles F. Wagner Jr. selling shares worth $28.65 million and $6.38 million respectively. Vertex Pharmaceuticals exceeded quarterly earnings estimates, reporting $4.80 EPS against $4.58 expected, and $3.08 billion in revenue, leading analysts to maintain a "Moderate Buy" rating with an average price target of $498.42.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $515 | $460 | +12% |
| 2025-12-05 | Morgan Stanley | $564 | $516 | +9% |
| 2025-12-03 | Morgan Stanley | $516 | $438 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-05 | Morgan Stanley | main | Overweight |
| 2025-12-03 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($3.52M) |
| Sells | 10 ($11.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Capital World Invest: 10.2% (-9.8%)
- Vanguard Group Inc: 9.5% (+1.0%)
- Blackrock Inc.: 8.8% (+1.7%)
- Capital Research Glo: 6.5% (+2.8%)
- JPMORGAN CHASE & CO: 5.1% (+119.3%)

### Key Risks

1. Heavy insider selling: $11M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- Momentum building: MRS_10 improving +2.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.58 indicates undervaluation relative to growth. Forward P/E 22.5x stretched relative to 10% growth. Quality metrics strong (ROE 22%, ROA 12%, margin 31%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.44), $1.1B free cash flow. Analyst sentiment positive (3 raises, avg +13%). Insider selling cluster ($11.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $116.6B |
| Beta | 0.32 |
| 52W Range | $362.50 - $519.68 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.58 |
| Forward P/E | 22.5 |
| Current P/E | 24.7 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.3% to 2.3% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.7pp (needs >3.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.79), confirming momentum. OFD pattern: -DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.28% (CS: 69) | Neutral |
| RSI_14 | 61.3 | Neutral |
| MACD Histogram | 0.79 | Bullish |
| vs SMA20 | 1.035x | Above |
| vs SMA50 | 1.063x | Above |
| vs SMA200 | 1.030x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $454.96
- **Stop Loss:** $433.72 (4.7% risk)
- **Target:** $476.20 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 47
- **Position Value:** $21,383.12
- **Portfolio %:** 21.38%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-09 (Est: $5.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.58 | $4.80 | +4.9% |
| 2025Q2 | $4.25 | $4.52 | +6.3% |
| 2025Q1 | $4.29 | $4.06 | -5.4% |
| 2024Q4 | $4.02 | $3.98 | -1.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*